Match!
Stefania Bellone
Yale University
118Publications
26H-index
2,107Citations
Publications 118
Newest
#1Luca Zammataro (Yale University)H-Index: 16
#2Salvatore Lopez (Yale University)H-Index: 14
Last.Alessandro D. Santin (Yale University)H-Index: 31
view all 45 authors...
The prognosis of advanced/recurrent cervical cancer patients remains poor. We analyzed 54 fresh-frozen and 15 primary cervical cancer cell lines, along with matched-normal DNA, by whole-exome sequencing (WES), most of which harboring Human-Papillomavirus-type-16/18. We found recurrent somatic missense mutations in 22 genes (including PIK3CA, ERBB2, and GNAS) and a widespread APOBEC cytidine deaminase mutagenesis pattern (TCW motif) in both adenocarcinoma (ACC) and squamous cell carcinomas (SCCs)...
#1Anna Bianchi (Yale University)H-Index: 4
#2Salvatore Lopez (Yale University)H-Index: 14
Last.Alessandro D. Santin (Yale University)H-Index: 31
view all 22 authors...
Abstract Objectives Cervical cancer (CC) remains a major health problem worldwide. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutics in ovarian cancer. We explored the preclinical in vitro and in vivo activity of olaparib against multiple primary whole exome sequenced (WES) CC cells lines and xenografts. Methods Olaparib cell-cycle, apoptosis, homologous-recombination-deficiency (HRD), PARP trapping and cytotoxic...
#1Burak Zeybek (Yale University)H-Index: 9
#2Aranzazu Manzano (Yale University)H-Index: 3
Last.Alessandro D. Santin (Yale University)H-Index: 31
view all 11 authors...
e17028Background: Recurrent disseminated cervical cancer is a discouraging clinical entity with 1-year survival rates between 10-15%, and development of novel, effective treatments remains an unmet...
#1Elena Bonazzoli (Yale University)H-Index: 12
#2Emiliano Cocco (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 22
Last.Alessandro D. Santin (Yale University)H-Index: 31
view all 24 authors...
Abstract Objective Aberrant expression of HER2/neu and PIK3CA gene products secondary to amplification/mutations are common in high-grade-serous-endometrial (USC) and ovarian-cancers (HGSOC). Because scant information is currently available in the literature on the potential negative effect of PIK3CA mutations on the activity of afatinib, in this study we evaluate for the first time the role of oncogenic PIK3CA mutations as a potential mechanism of resistance to afatinib in HGSOC and USC overexp...
12345678910